Insider Selling: Gritstone Oncology Inc (NASDAQ:GRTS) Insider Sells 10,000 Shares of Stock
Gritstone Oncology Inc (NASDAQ:GRTS) insider Raphael Rousseau sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $10.76, for a total value of $107,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of NASDAQ:GRTS traded down $0.60 during trading on Friday, reaching $9.45. The stock had a trading volume of 267,758 shares, compared to its average volume of 185,599. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.22 and a current ratio of 10.22. The business has a fifty day moving average price of $10.39 and a 200-day moving average price of $11.35. The stock has a market cap of $367.75 million and a PE ratio of -1.30. Gritstone Oncology Inc has a 1-year low of $8.75 and a 1-year high of $32.90.
Gritstone Oncology (NASDAQ:GRTS) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.01). The firm had revenue of $1.15 million during the quarter, compared to analyst estimates of $1.20 million. Gritstone Oncology had a negative return on equity of 83.79% and a negative net margin of 2,038.71%. Sell-side analysts expect that Gritstone Oncology Inc will post -2.6 earnings per share for the current year.
Several analysts have commented on GRTS shares. Robert W. Baird started coverage on Gritstone Oncology in a report on Thursday, July 25th. They issued an “outperform” rating and a $17.00 price objective on the stock. Cowen reissued a “buy” rating on shares of Gritstone Oncology in a report on Monday, May 13th. ValuEngine raised Gritstone Oncology from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research lowered Gritstone Oncology from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $20.00.
About Gritstone Oncology
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
See Also: Market Timing
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.